In a nutshell This study examined the effectiveness of vibration therapy on patients receiving chemotherapy for leukemia and lymphoma. Researchers found that vibration therapy improved daily function in these patients. Some background Exercise is proven to be effective in improving outcomes of patients with cancer. Chemotherapy treatment can make...
Read More
In a nutshell This study evaluated the long-term outcomes of patients with advanced Hodgkin’s lymphoma (HL) who received intensive first-line treatment. This study concluded that intensive first-line treatment with or without radiotherapy led to better long-term outcomes in these patients. Some background For patients with advanced HL,...
Read More
In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...
Read More
In a nutshell This study investigated the outcomes of reduced-intensity conditioning followed by allogeneic stem cell transplantation (alloSCT) in patients with Hodgkin’s lymphoma (HL). This study concluded that this treatment improved survival outcomes in these patients. Some background AlloSCT is an effective therapy for patients with HL who...
Read More
In a nutshell This study investigated the risk factors of developing lung problems after bleomycin (Blenoxane) treatment for Hodgkin lymphoma (HL). It was found that older age may increase the risk of developing lung problems. Some background Bleomycin is an anti-cancer drug, used to treat many types of cancer. Bleomycin is commonly...
Read More
In a nutshell This paper summarised the side effects associated with the use of nivolumab (Opdivo) for the treatment of Hodgkin Lymphoma. The main finding was that patients treated with nivolumab may experience immune-related side effects. Some background Brentuximab vedotin (Adcetris) and stem cell transplant are often used to treat classical...
Read More
In a nutshell This study evaluated the outcomes of brentuximab vedotin (Adcetris) treatment for patients with relapsed (recurrent) or progressive (tumor grows or spreads) Hodgkin’s lymphoma (HL) after allogeneic (allo) stem cell transplantation (SCT). This study concluded that brentuximab vedotin is safe and effective for these patients. Some...
Read More
In a nutshell This study investigated the effectiveness of medical cannabis in managing side effects associated with chemotherapy in patients with Hodgkin’s lymphoma (HL). This study concluded that medical cannabis may be effective in relieving therapy-related side effects in these patients. Some background Chemotherapy remains the standard...
Read More
In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...
Read More
In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...
Read More
In a nutshell This article provided the ESMO guidelines for the treatment of Hodgkin’s lymphoma (HL). Some background Hodgkin’s lymphoma (HL) comprises 10% of new lymphoma cases in the U.S., with 21% of these occurring in adolescents. Thanks to advancements in treatment, mortality rates have decreased dramatically. 90% of patients...
Read More
In a nutshell This study evaluated the effectiveness of short-course (2 cycles) ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with interim PET scanning in previously untreated patients with early-stage (stage 1 – 2) Hodgkin’s lymphoma (HL). This study concluded that short-course ABVD was effective in the majority of...
Read More
